Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DG8VN2
|
|||
| Drug Name |
UX143
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Osteogenesis imperfecta [ICD-11: LD24.K0; ICD-10: Q78.0; ICD-9: 756.51] | Phase 3 | [1] | |
| Company |
Ultragenyx Pharmaceutical Novato, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sclerostin (SOST) | Target Info | . | [2] |
| KEGG Pathway | Wnt signaling pathway | |||
| NetPath Pathway | TWEAK Signaling Pathway | |||
| Reactome | TCF dependent signaling in response to WNT | |||
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05768854) An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.